by nms-sync | Oct 1, 2022 | News
Accelera Srl Announces Change in Board Composition Effective Today
Nerviano_October_1_2022_Accelera Srl, leading CRO and a member of the NMS Group today announced the change in its Board Composition, following the resignation of its board member Enrico...
by Sidney | Sep 7, 2022 | Events, News
Dr. Simone Pollo main research interests are the ethics of human/animal relationships and the naturalization of ethics. He is MA in Philosophy at Sapienza University of Rome (1995) and PhD in Bioethics at the University of Genoa (2011). He is currently Associate...
by nms-sync | Aug 3, 2022 | News
NMS Group S.p.A, an oncology R&D powerhouse with a biotech discovering and developing innovative therapies for the treatment of cancer, a CRO and CDMO that together push Oncology Forward, has announced the appointment of Andrew Curtis as Chief Strategy Officer...
by nms-sync | Jun 29, 2022 | News
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
“2021 was a challenging yet rewarding year for our Group. As we firmly believe...
by nms-sync | May 5, 2022 | News
Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A...
by nms-sync | Feb 7, 2022 | News
Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of...
Welcome and Check out our new motion picture!
Recent Comments